25 May 2023

BSF Enterprise PLC

("BSF" or the "Company")

Admittance to trading on the OTCQB Venture Market

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that the Company's Ordinary Shares ("Ordinary Shares") were admitted to trading on the OTCQB Venture Market in the United States on 24 May 2023.  The shares trade under the symbol BSFAF.

Trading on the OTCQB market provides BSF with access to one of the world's largest investment markets, expanding the Company's reach to a broader pool of investors while creating the potential for greater liquidity in its shares. Shares will also be available to US investors during US trading hours, priced in US dollars. This will ease cross-border trading, with the potential to further enhance liquidity.

There is no capital raise associated with BSF trading on the OTCQB market and BSF's Ordinary Shares will continue to trade on its primary listing, the Main Market of the London Stock Exchange, under the ticker BSFA.

Che Connon, Managing Director of BSF Enterprise and CEO at 3D Bio Tissues, commented: "We are delighted to have joined the OTCQB market. This is an important step for BSF which provides access to a wider investor audience from which to raise funds and improve liquidity. In addition, it will help to raise our profile in the US and beyond, a timely development given that we are in the process of establishing sales channels across key global markets including the US. This was demonstrated in our announcement released earlier this week, detailing the headway we are already making in delivering new contracts and distribution partners. Together, these developments give us confidence in our ability to drive additional momentum in the coming months."

Further Information on BSF's application and the OTCQB market below:

As a Foreign Private Issuer, BSF's onboarding to the OTC Markets is based on satisfaction of the requirements for OTCQB as applicable to international reporting companies including satisfaction of the criteria for the exemption under the US Exchange Act Rule 12g3-2(b) from SEC reporting. The Rule 12g3-2(b) exemption includes the disclosure obligation to ensure that certain information made public or distributed under home market regulations is made publicly available on the Company's website or other electronic information delivery system in English. Thus, the Company will have no additional reporting obligations and incur minimal ongoing costs, compared to traditional major exchanges.

As a verified market, the OTCQB offers transparent trading for companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. The cross-trading facility is provided through OTC Markets Group Inc., located in New York. OTC Markets operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-listed companies. Online brokers such as Ameritrade, Fidelity Investments, Tradestation, Charles Schwab and E-trade all offer OTCQB trades. US investors can find real-time quotes, market information and access current company news and developments on a BSF page on the OTC Markets website after the application is completed .

BSF has appointed B. Riley Financial Company as its OTCQB Sponsor and is advised by Ince & Co Lawyers in London.

Additional information about the OTCQB market can be found at:

www.otcmarkets.com/learn/market-101

-Ends-

For further enquiries, please visit www.bsfenterprise.com or contact:

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.